EXACT Therapeutics AS: Primary insider notification
EXACT Therapeutics AS: Primary insider notification
In connection with the re-election of Jonathan Allis to the board of directors of EXACT Therapeutics AS ("EXACT-Tx" or the "Company"), Jonathan Allis has been granted 569,370 options in the Company which will vest on a quarterly basis. With the addition of the 63,263 options previously granted, Mr. Allis now has a total of 632,633 options.
Please see the attached notification form for further information.
This information is subject to the disclosure requirements in section 5-12 of the Norwegian Securities Trading Act.
For more information, please contact:
Per Walday, CEO
EXACT Therapeutics
Email [email protected]
About EXACT-Tx:
EXACT-Tx is a clinical-stage precision medicine company utilizing the power of ultrasound and microbubbles to enable targeted drug delivery in oncology. Acoustic Cluster Therapy (ACT®) follows a unique approach and may be applied to a wide range of therapeutic agents across a multitude of indications including within oncology (chemotherapy, immunotherapy) and brain diseases. www.exact-tx.com